NEW YORK – Amgen on Wednesday said it has submitted a new drug application to the US Food and Drug Administration for its KRAS inhibitor sotorasib as a treatment for previously treated, locally advanced, or metastatic non-small cell lung cancer patients whose tumors harbor KRAS G12C mutations.